AEMDHealthcare · Medical DevicesThe 2 Wall Street analysts covering Aethlon Medical, Inc. hold a median 12-month price target of $13 — +385.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Aethlon Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (1): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AEMD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +385.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | $1.50 |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 7 July 2025 | HC Wainwright & Co. | Assumes | Neutral | $1.50 |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2022 | Maxim Group | Downgrade | Hold | — |
| 25 June 2021 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $9.00 |
| 1 June 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Jan 2021 | Maxim Group | Initiates | Buy | — |
| 25 Nov 2020 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | H.C. Wainwright | Initiates | Buy | — |
| 20 Nov 2017 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AEMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aethlon Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aethlon Medical, Inc. held its Q1 2027 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — Earnings calls provide a direct update from management on the company's recent financial results and operational progress.
Aethlon Medical, a clinical-stage medical therapeutic company, announced its financial results for the fiscal first quarter ended June 30, 2026, and provided a corporate update on its Hemopurifier program. The company scheduled an earnings conference call for today at 4:30 p.m. ET.
Why it matters — AEMD watchers would care because this update details the company's first-quarter financial performance and the latest progress on its Hemopurifier program.
Aethlon Medical announced it will release its fiscal first quarter financial results for the period ended June 30, 2026, on August 13, 2026, followed by a conference call.
Why it matters — The financial results and conference call will provide an update on the company's performance and strategic outlook for the fiscal year.
The 2 Wall Street analysts covering Aethlon Medical, Inc. have a median 12-month price target of $13, with estimates ranging from $1.5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Aethlon Medical, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aethlon Medical, Inc. 25 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Aethlon Medical, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +385.3% from the last close, and Ticker Nerd's factor model ranks Aethlon Medical, Inc. 25 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aethlon Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $25 over the next 12 months.
Aethlon Medical Inc. is a medical technology company focused on developing immunotherapeutic products for cancer and infectious disease.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Aethlon Medical, Inc. (AEMD) Q1 2027 Earnings Call Transcript". Aethlon Medical, Inc. held its Q1 2027 earnings call, the transcript of which was published by Seeking Alpha.
Aethlon Medical Inc. is a medical technology company focused on developing immunotherapeutic products for cancer and infectious disease. Its primary platform, the Aethlon Hemopurifier, is designed to reduce cancer-promoting exosomes and circulating viruses through extracorporeal blood filtration. The company’s work centers on clinical-stage solutions that address life- and organ-threatening conditions, with applications that intersect oncology, virology, and critical care medicine. Aethlon Medical serves the broader healthcare market by advancing device-based technologies intended for diagnostic and therapeutic use in severe diseases. Headquartered in San Diego, California, Aethlon Medical Inc. operates as a specialized developer of highly targeted medical treatments within the biotechnology and medical device sectors.
CEO Mr. James B. Frakes M.B.A. · 9 employees · United States · https://www.aethlonmedical.com